Reached alignment with the FDA on the final design of the ENABLE-2 pivotal Phase 3 trial On track to initiate ENABLE-2 before year-end 2026 Strong balance sheet with $884 million in cash, cash equivalents and marketable
Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readinessEnliven continues preparation for late-stage development and commercialization, as it plans to
Enliven remains on track to initiate ENABLE-2 before year-end 2026BURLINGAME, Calif., Oct. 6, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical
BURLINGAME, Calif., Sept. 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule
BURLINGAME, Calif., Aug. 31, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule
Announced positive Phase 1 clinical data for ELVN-001 in CML, demonstrating encouraging ELVN-001 efficacy data and a favorable safety and tolerability profileReached alignment with the FDA on key Phase 3 trial design
BURLINGAME, Calif., June 15, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule
BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule
BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule
61% overall MMR and 48% MMR achievement by 24 weeks in the 80 mg QD Phase 1b cohort67% overall MMR and 55% MMR achievement by 24 weeks in all Phase 1b patients who had previously received 1 or 2 prior unique
Enliven will host a webcast conference call on June 11, at 8:30 a.m. ETBURLINGAME, Calif., June 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage
BOULDER, Colo., May 21, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (NASDAQ:ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule
Abstract includes previously reported data: cumulative MMR rate of 47% with 38% of patients achieving MMR by 24 weeks in mature, heavily pretreated 80 mg QD Phase 1b cohortIn patients who previously received asciminib,
Phase 1 data update for ELVN-001 expected mid-2026 Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026Strong balance sheet with $452 million in cash, cash equivalents and
Reported positive initial Phase 1b data for ELVN-001 in CML Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 expected in the second half of 2026Key data readout, regulatory interactions, and operational
